Boston, MA 的 頭頸部癌症 臨床試驗
22 項針對 頭頸部癌症 的研究正在 Boston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
招募中2/3 期
- Site #0131, Boston
- Site#0101, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
招募中
- Dana-Farber Cancer Institute, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
招募中1 期
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Toripalimab With Chemotherapy for Sinus Cancer
招募中2 期
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
招募中2 期
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- Massachusetts General Hospital Cancer Center, Boston
Jump: MR Simulation For Radiation Therapy Master Protocol
招募中
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
PDT For Induction Therapy For Head And Neck Cancer
招募中2 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
招募中觀察性研究
- Dana-Farber Cancer Institute, Boston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
招募中1/2 期
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
招募中2 期
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
招募中1/2 期
- Massachusetts General Hospital,, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
招募中
- Dana Farber Cancer Institute, Boston
Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy
招募中
- Brigham and Women's Hospital, Boston
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
招募中早期第 1 期
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
招募中1/2 期
- Dana Farber Cancer Institute, Boston
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
招募中1 期
- Dana Farber/Partners Cancer Care Inc, Boston
Comprehensive Outcomes for After Cancer Health
招募中歡迎健康志工
- Dana Farber Cancer Institute, Boston
其他城市的 頭頸部癌症 試驗
- Houston, TX30 項研究
- Nashville, TN21 項研究
- New York City, NY21 項研究
- St. Louis, MO15 項研究
- Dallas, TX12 項研究
- Pittsburgh, PA11 項研究
- San Antonio, TX10 項研究
- Los Angeles, CA10 項研究
- Baltimore, MD10 項研究
- Washington, DC10 項研究
- Durham, NC10 項研究
- Chicago, IL10 項研究
Boston 的其他研究
- 乳癌112 項研究
- 非小細胞肺癌90 項研究
- 癌症（所有類型）85 項研究
- 轉移性癌症63 項研究
- 大腸直腸癌63 項研究
- 肺癌62 項研究
- 卵巢癌61 項研究
- 前列腺癌59 項研究
- 憂鬱症52 項研究
- 子宮內膜癌50 項研究
- 心臟衰竭44 項研究
- 急性髓系白血病44 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。